|
| | Abiraterone Impurity 4 Basic information |
| Product Name: | Abiraterone Impurity 4 | | Synonyms: | Abiraterone Impurity 4;(3S,8R,9S,10R,13S,14S)-17-Ethyl-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate;Pregna-5,16-dien-3-ol, 3-acetate, (3β)-;Pregna-5,16-dien-3β-ol Acetate;Abiraterone Impurity 50;Abiraterone Impurity 01;Abiraterone Impurity 52 | | CAS: | 2118-32-3 | | MF: | C23H34O2 | | MW: | 342.52 | | EINECS: | | | Product Categories: | | | Mol File: | 2118-32-3.mol |  |
| | Abiraterone Impurity 4 Chemical Properties |
| Melting point | 173-174 °C | | Boiling point | 423.8±45.0 °C(Predicted) | | density | 1.05±0.1 g/cm3(Predicted) |
| | Abiraterone Impurity 4 Usage And Synthesis |
| Uses | Pregna-5,16-dien-3β-ol Acetate is an impurity of Abiraterone (A108490), a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer. (Abiraterone Impurity 4). |
| | Abiraterone Impurity 4 Preparation Products And Raw materials |
|
